PD-1/PD-L1 Inhibitors Show Promise in Thyroid Cancer Treatment Through Combination Strategies
Key Insights
PD-1 (search)/PD-L1 (search) inhibitors demonstrate modest efficacy as monotherapy in thyroid cancer (search), with objective response rates ranging from 6.8% to 30% depending on cancer subtype and PD-L1 expression levels.
Combination therapies with targeted agents like BRAF inhibitors, chemotherapy, and radiotherapy show significantly improved outcomes compared to monotherapy, particularly in anaplastic thyroid carcinoma (search) patients.
Traditional Chinese medicine compounds and natural products present novel combination opportunities, potentially enhancing immune responses while reducing toxicity through multi-target mechanisms.
Thyroid cancer (search) represents one of the most common endocrine malignancies, with rising incidence rates particularly affecting women. While most differentiated thyroid cancers respond well to conventional treatments including surgery and radioactive iodine therapy, advanced, poorly differentiated, and anaplastic subtypes remain challenging to treat and exhibit poor survival outcomes.
Recent advances in understanding tumor immune escape mechanisms have opened new therapeutic avenues through immune checkpoint inhibition. The PD-1 (search)/PD-L1 (search) pathway plays a crucial role in thyroid cancer (search) immune evasion, with significantly elevated PD-L1 expression observed in invasive thyroid cancer subtypes compared to benign lesions.
PD-L1 Expression Patterns Vary Across Thyroid Cancer Subtypes
Analysis of 407 thyroid cancer (search) specimens revealed notable heterogeneity in PD-L1 (search) expression across different subtypes. Immunohistochemical positivity rates were 6.1% in papillary thyroid carcinoma (search) (PTC), 7.6% in follicular thyroid carcinoma (search) (FTC), and 22.2% in anaplastic thyroid carcinoma (search) (ATC). PD-L1 expression correlated with aggressive features including lymph node metastasis, extrathyroidal extension, and BRAF V600E (search) mutations.
However, reported PD-L1 (search) positivity rates vary widely across studies, ranging from 6.1% to 82.5%. This variability stems from differences in antibody clones, detection platforms, scoring criteria, and potential interference from autoimmune thyroid conditions like Hashimoto's thyroiditis.
Molecular Mechanisms Drive PD-L1 Upregulation
Several key pathways regulate PD-L1 (search) expression in thyroid cancer (search). The BRAF V600E (search) mutation, present in many thyroid cancers, positively correlates with PD-L1 levels through MEK/ERK signaling activation. Single-cell RNA sequencing of ATC samples harboring BRAF V600E mutations showed significantly elevated CD274 expression scores.
The PI3K/AKT (search) pathway also contributes to PD-L1 (search) regulation, with research confirming that leptin and insulin dose-dependently upregulate PD-L1 via this signaling cascade. This effect is enhanced in the presence of activating PIK3CA mutations like E545K.
MicroRNA regulation provides another layer of control, with restoration of miR-199a-5p expression suppressing both PD-L1 (search) and Claudin-1, thereby inhibiting thyroid cancer (search) cell proliferation, migration, and invasion.
Clinical Trials Reveal Mixed Results for Monotherapy
Clinical evaluation of PD-1 (search)/PD-L1 (search) inhibitors as monotherapy has shown modest but variable results. The phase Ib KEYNOTE-028 trial of pembrolizumab in PD-L1-positive advanced differentiated thyroid cancer (search) enrolled 22 patients, achieving an objective response rate of 9% and median progression-free survival of 7 months.
The larger phase II KEYNOTE-158 trial included 103 thyroid cancer (search) patients, demonstrating an objective response rate of 6.8%, median overall survival of 34.5 months, and median progression-free survival of 4.2 months. Treatment-related adverse events occurred in 69.9% of patients.
Spartalizumab showed more promising results in anaplastic thyroid carcinoma (search), with approximately 30% response rates among PD-L1 (search)-positive patients (expression ≥1%) and good overall tolerability in a phase II trial of 42 metastatic ATC patients.
Combination Strategies Show Enhanced Efficacy
Recognizing the limitations of monotherapy, researchers have explored various combination approaches with encouraging results. Targeted combination immunotherapy has emerged as particularly promising, with preclinical studies showing that lenvatinib plus pembrolizumab effectively reduces tumor burden and prolongs survival in immunocompetent ATC mouse models.
A stratified study of 42 ATC patients received targeted therapy based on mutation status: vemurafenib/cobimetinib for BRAF V600E (search) mutations, cobimetinib for RAS/NF mutations, or bevacizumab for wild-type tumors, each combined with atezolizumab. This combination therapy significantly extended median overall survival compared to historical controls.
The FDA-approved combination of dabrafenib plus trametinib for BRAF V600E (search)-mutant ATC has shown further improvement when combined with pembrolizumab. A retrospective study demonstrated that this triple combination significantly prolonged survival in BRAF-mutant ATC patients, though with increased but manageable toxicity.
Dual Checkpoint Inhibition and Novel Approaches
Dual immune checkpoint inhibition targeting both PD-1 (search) and CTLA-4 (search) has shown therapeutic potential. A trial of nivolumab plus ipilimumab in advanced thyroid carcinoma achieved a clinical benefit rate of 50% in the ATC subgroup, though it did not meet predefined endpoints for differentiated thyroid cancer (search) patients.
Emerging therapeutic strategies include oncolytic viruses, CAR-T cell therapy, and epigenetic interventions. Histone deacetylase inhibitors like vorinostat and valproic acid have been shown to promote PD-L1 (search) upregulation in ATC cells, particularly when combined with chemotherapy, suggesting potential for enhancing immunotherapy efficacy.
Traditional Medicine Offers Complementary Benefits
Traditional Chinese medicine compounds present novel combination opportunities through multi-target mechanisms. Natural compounds like silybin (search) inhibit AKT phosphorylation and downstream survival pathways, while curcumin reduces PD-L1 (search) expression through AKT/mTORC1/STAT3 pathway inhibition.
Ginseng polysaccharides enhance sensitivity to PD-1 (search) inhibitors by improving gut microbiota structure and increasing beneficial microbial metabolites. The Shenmai injection adjusts the tumor immune microenvironment by inducing NK cell infiltration, showing superior synergistic effects when combined with PD-1 inhibitors in non-small cell lung cancer (search) models.
Future Directions and Challenges
While PD-1 (search)/PD-L1 (search) inhibitors represent a promising therapeutic frontier for thyroid cancer (search), several challenges remain. The broad clinical application still requires overcoming resistance mechanisms, optimizing patient selection criteria, and managing immune-related adverse events.
Current research focuses on identifying predictive biomarkers, understanding resistance mechanisms, and developing standardized combination protocols. The integration of traditional medicine approaches with modern immunotherapy offers particular promise for achieving enhanced efficacy while minimizing toxicity.
The field continues to evolve rapidly, with ongoing clinical trials exploring novel combinations and treatment sequences. Success will likely depend on personalized approaches that consider tumor genetics, immune microenvironment characteristics, and patient-specific factors to optimize therapeutic outcomes in this challenging disease.